Matinas BioPharma Holdings, Inc. (MTNB) stock
MTNBNYSEPharmaceutical PreparationsFiscal year ends December 31
$0.91+0.05 (+6.35%)
Close on Nov 18, 2026Market cap $13.37MP/E –Yield –
Matinas BioPharma operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Matinas BioPharma's operating cash flow for the twelve months ending Jun 30, 2026 was -$6.42M. For fiscal 2025 it was -$7.01M. The highest annual figure on record is -$2.99M in fiscal 2013.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$7.01M | – |
| FY2024 | Dec 31, 2024 | -$15.89M | – |
| FY2023 | Dec 31, 2023 | -$15.28M | – |
| FY2022 | Dec 31, 2022 | -$19.16M | – |
| FY2021 | Dec 31, 2021 | -$15.22M | – |
| FY2020 | Dec 31, 2020 | -$17.37M | – |
| FY2019 | Dec 31, 2019 | -$14.09M | – |
| FY2018 | Dec 31, 2018 | -$10.32M | – |
| FY2017 | Dec 31, 2017 | -$11.46M | – |
| FY2016 | Dec 31, 2016 | -$6.12M | – |
| FY2015 | Dec 31, 2015 | -$7.81M | – |
| FY2014 | Dec 31, 2014 | -$7.96M | – |
| FY2013 | Dec 31, 2013 | -$2.99M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$1.84M | – |
| Q1 FY2026 | Mar 31, 2026 | -$1.60M | – |
| Q4 FY2025 | Dec 31, 2025 | -$1.51M | – |
| Q3 FY2025 | Sep 30, 2025 | -$1.47M | – |
| Q2 FY2025 | Jun 30, 2025 | -$2.02M | – |
| Q1 FY2025 | Mar 31, 2025 | -$2.01M | – |
| Q4 FY2024 | Dec 31, 2024 | -$3.51M | – |
| Q3 FY2024 | Sep 30, 2024 | -$3.50M | – |
| Q2 FY2024 | Jun 30, 2024 | -$3.11M | – |
| Q1 FY2024 | Mar 31, 2024 | -$5.77M | – |
| Q4 FY2023 | Dec 31, 2023 | -$4.58M | – |
| Q3 FY2023 | Sep 30, 2023 | -$4.42M | – |
| Q2 FY2023 | Jun 30, 2023 | -$2.19M | – |
| Q1 FY2023 | Mar 31, 2023 | -$4.09M | – |
| Q4 FY2022 | Dec 31, 2022 | -$4.30M | – |
| Q3 FY2022 | Sep 30, 2022 | -$4.97M | – |
| Q2 FY2022 | Jun 30, 2022 | -$5.13M | – |
| Q1 FY2022 | Mar 31, 2022 | -$4.76M | – |
| Q4 FY2021 | Dec 31, 2021 | -$3.96M | – |
| Q3 FY2021 | Sep 30, 2021 | -$5.75M | – |
| Q2 FY2021 | Jun 30, 2021 | -$864.66K | – |
| Q1 FY2021 | Mar 31, 2021 | -$4.65M | – |
| Q4 FY2020 | Dec 31, 2020 | -$4.31M | – |
| Q3 FY2020 | Sep 30, 2020 | -$5.23M | – |
| Q2 FY2020 | Jun 30, 2020 | -$3.17M | – |
| Q1 FY2020 | Mar 31, 2020 | -$4.66M | – |
| Q4 FY2019 | Dec 31, 2019 | -$4.90M | – |
| Q3 FY2019 | Sep 30, 2019 | -$4.07M | – |
| Q2 FY2019 | Jun 30, 2019 | -$2.10M | – |
| Q1 FY2019 | Mar 31, 2019 | -$3.02M | – |
| Q4 FY2018 | Dec 31, 2018 | -$2.62M | – |
| Q3 FY2018 | Sep 30, 2018 | -$2.64M | – |
| Q2 FY2018 | Jun 30, 2018 | -$2.26M | – |
| Q1 FY2018 | Mar 31, 2018 | -$2.81M | – |
| Q4 FY2017 | Dec 31, 2017 | -$1.92M | – |
| Q3 FY2017 | Sep 30, 2017 | -$2.78M | – |
| Q2 FY2017 | Jun 30, 2017 | -$3.73M | – |
| Q1 FY2017 | Mar 31, 2017 | -$3.03M | – |
| Q4 FY2016 | Dec 31, 2016 | -$2.12M | – |
| Q3 FY2016 | Sep 30, 2016 | -$1.37M | – |
See a number that looks wrong?